Business Context and Reporting Period
This Form 8-K/A (Amendment No. 1) was filed by DaVita Inc. on June 20, 2019, regarding events occurring on June 19, 2019. The filing serves two primary purposes: to confirm the completion of the disposition of the DaVita Medical Group division and to amend a previously filed pro forma financial statement to remove a specific line item labeled "Provision for uncollectible accounts."
Key Financial Metrics and Transaction Details
- Transaction Type: Disposition of all issued and outstanding equity interests of DaVita Medical Holdings, LLC (DaVita Medical Group division).
- Buyer: Collaborative Care Holdings, LLC, a wholly owned subsidiary of Optum, Inc. (UnitedHealth Group Incorporated).
- Purchase Price: Aggregate of $4,340,000,000, subject to customary purchase price adjustments.
- Financial Statements: The filing references unaudited pro forma consolidated balance sheets as of March 31, 2019, and statements of income for the year ended December 31, 2018, and the three months ended March 31, 2019. Specific revenue, profit, or cash flow figures for the consolidated entity are not detailed in this text; they are contained in the referenced Exhibit 99.1.
Material Changes and Amendments
The primary material change reported is the completion of the sale of the DaVita Medical Group division to Optum. Additionally, this Amendment No. 1 specifically corrects the pro forma unaudited consolidated statement of income for the quarter ended March 31, 2019, by removing the line item and related amount for "Provision for uncollectible accounts" that appeared in the original filing. The filing states that no other updates or modifications to the original 8-K or the joint press release are made.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the intended use of net proceeds from the sale. Management explicitly states that actual results could differ materially due to known and unknown risks. These risks include those set forth in DaVita's most recent Form 10-Q and subsequent SEC reports. The company undertakes no obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the final purchase price after customary adjustments by reviewing the definitive closing documents.
- Review Exhibit 99.1 for the corrected unaudited pro forma financial statements to understand the impact of the disposition on DaVita's financial position.
- Confirm the specific use of the approximately $4.34 billion in net proceeds as outlined in the joint press release (Exhibit 99.2).
- Assess the impact of removing the "Provision for uncollectible accounts" line item on the pro forma income statement for the quarter ended March 31, 2019.